Use access key #2 to skip to page content.

EPS100Momentum (71.54)

Prostate Cancer cases could be rising further with men holding cell phones in pockets, they need a clinical trial for this asap.

Recs

1

November 16, 2010 – Comments (2) | RELATED TICKERS: DNDN , EDAP

Nov 16, 2010 12:30 PM | about stocks: DNDN, EDAP

I am one of those men that love to keep cell phones in my pants pockets. Although no studies that I know of have been done on men that keep cell phones in their pockets vs. those that don't for prostate cancer. I believe this is one study that needs to be done asap.
Cell Phone use and Cancer article

November 16, 2010 07:16 AM Eastern Time  Research and Markets: Prostate Cancer Drug Futures 2010 - the Market is Set to Change with the Arrival of New Therapies That Will Prolong a Patient's Survival  

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/8f38a8/prostate_cancer_dr) has announced the addition of the "Prostate Cancer Drug Futures 2010" report to their offering.

The prostate cancer (PC) market is on the verge of considerable change with the imminent arrival of new targeted therapies that will prolong patient survival. PC is the second leading cause of new cancer cases in men worldwide and the sixth leading cause of cancer death in men. In the US, over two million men currently suffer with PC and it is estimated that there were 192,311 new cases and 29,698 deaths due to the disease in 2008. There have been dramatic improvements in PC survival over the last 25 years, mainly due to a combination of earlier diagnosis and improvements in treatments, although rates vary between countries

The PC market was estimated to be worth US$5.2 billion in 2008; it is one of the larger segments of the oncology market, alongside breast, non-small cell lung and colorectal cancers. The market is currently driven by the use of hormonal therapies, which are prescribed mainly for advanced hormone-dependent PC. However, the market dynamics will change considerably over the next six years as patents expire and generic competition intensifies. Research into new therapies is extremely active and new agents with novel modes of action are being evaluated.

NOW YOU CAN STAY IN TOUCH WITH THE DEVELOPMENTS WHICH MATTER:

This all new web service, Prostate Cancer Drug Futures, assesses the future prospects for market success for individual drugs. Based on independent research and proprietary analysis, each product assessed brings the prospects for a product into clear focus. Best of all, each drug is regularly reviewed ensuring that latest developments are incorporated for you to see.

WITH EACH KEY DRUG ANALYSED IN THIS SERVICE YOU CAN:

Track the drugs progress and stay abreast of developmentsUnderstand the drugs novelty and mode of actionEvaluate the strength of the company developing/producing the drugReview opportunities and challenges with Espicoms unique 5-point competitive assessmentKnow the launch timeframe for new products or indicationsBe aware of promising mid-stage development candidatesEstimate future revenues with original 5-year forecasts for launched and leading pipeline candidatesReview significant clinical trial results

STRUCTURED ANALYSIS OF KEY DRIVERS AND DAMPENERS OF SUCCESS:

For each product analysed there is an extensive and standardised review of the factors which can affect its clinical and commercial performance. Those factors include:

Novelty/rationale for mechanism of actionCurrent statusProof of concept/clinical dataDevelopment risksCompany expertiseCompetition within the market-placeSales forecast (for key late-stage and launched products)Competitor ratio analysis scoreClinical trial results

OVER 45 PROSTATE DRUGS COVERED IN THIS REPORT, SOME INCLUDE:

ApprovedBicalutamideCabazitaxelDegarelixDocetaxelMitoxantronePaclitaxelSipuleucel-TFiledDutasteridePhase IIIAbiraterone acetateBortezomibCixutumumabE75 GM-CSF adjuvant vaccineEnzastaurinFigitumumabIxabepiloneSagopiloneVadimezan

To view all drugs covered in this report and for more information visit http://www.researchandmarkets.com/research/8f38a8/prostate_cancer_dr

Source: Espicom Business Intelligence Ltd

Stocks: DNDN, EDAP

 

2 Comments – Post Your Own

#1) On November 16, 2010 at 2:54 PM, TMFCrocoStimpy (81.02) wrote:

With regards to cell phones and prostate cancer, the radiation emissions of concern are occurring while the phone is in use, not the low emission mode of reception.  So, unless you are talking with your phone still in your pocket, there is no real question to even be asked here (if you are using it via bluetooth, maybe I could see asking the question).

 

Report this comment
#2) On December 12, 2010 at 2:30 PM, hiddenflem (77.27) wrote:

A clinical trial would not be the best way to answer this question--think about how long it takes for prostate cancer to develop, how difficult it would be to get people to adhere to carrying cell phones according to how you tell them for such a long period of time. I'm sure some of the cohort studies have data on cell phone use although I doubt many have info on where cell phones are kept. If they do I guarantee people are analysing that data right now.

Report this comment

Featured Broker Partners


Advertisement